A Study of LY4302814 in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07566338
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • LY4302814 — DRUG
    Administered SC
  • LY4302814 — DRUG
    Administered IV
  • Placebo — DRUG
    Administered SC
  • Placebo — DRUG
    Administered IV

Study Details

The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4302814 IV
    LY4302814 administered intravenously (IV)
  • Placebo Comparator: Placebo IV
    Placebo administered IV
  • Experimental: LY4302814 SC
    LY4302814 administered subcutaneously (SC)
  • Placebo Comparator: Placebo SC
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Day 1 through Day 197 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117
866-429-3700
Chiamaka Iheme (PRINCIPAL_INVESTIGATOR)

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit· Daytona Beach, FL

Related Studies